Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment

Atossa Therapeutics CEO Steven Quayjoined Steve Darling from Proactive to discuss the continued advancement of the company’s lead investigational therapy, (Z)-Endoxifen, and its potential applications across multiple breast cancer indications as well as certain rare diseases. The discussion highlighted the scientific foundation of the program, recent clinical data presentations, and key milestones expected in the months ahead. Quay explained that Atossa Therapeutics was founded with a clear mission focused on improving the prevention and treatment of breast cancer. Central to that strategy is the development of (Z)-Endoxifen, a therapy derived from decades of clinical experience and scientific understanding surrounding tamoxifen, one of the most widely prescribed treatments for hormone receptor-positive breast cancer. While tamoxifen has been a standard therapy for many years, its effectiveness depends on a patient’s ability to metabolize the drug into its active form, Endoxifen....